PHIO (Phio Pharmaceuticals) Short Interest


PHIO Phio Pharmaceuticals Corp PHIO
28 GF Score
Price $1.02
! 1 Warning Sign
View Full Analysis

What is Phio Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PHIO vs PBM, KPRX, OSRH: Short Interest Comparison

For the Biotechnology subindustry, Phio Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phio Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Short Interest falls into.


PHIO
28GF Score
Phio Pharmaceuticals Corp PHIO
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phio Pharmaceuticals Business Description

Address 411 Swedeland Road, Suite 23-1080, King of Prussia, PA, USA, 19406
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score

Get the complete analysis for PHIO

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price